Horizon Pharma, Inc. Announces Results of Phase 3 Study of Lodotra Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis - Drugs.com MedNews
Links shared publicly online about this topic.
- 999total visits
Horizon Pharma, Inc. Announces Results of Phase 3 Study of Lodotra Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis - Drugs.com MedNews
- Results published in July Issue of Annals of Rheumatic Diseases - Horizon Pharma, Inc. announced today the results from the extended open label portion of The
View full resource at drugs.com
Tags: Arthritis, Rheumatoid Arthritis, Disease and Condition, Pharma, Phase 3 Clinical Trial
Most Recently Shared on July 24, 2010 at 12:44 pm By:
Horizon Pharma, Inc. Announces Results of Phase 3 Study of Lodotra Demonstrate 12-Month Sustained Efficacy and Saf... http://bit.ly/cQkH1c
Advertisement
